TG-101348 (Fedratinib), a selective JAK2 inhibitor approved for myelofibrosis (Mullally et al., 2020), has not yet been tested in sepsis but may exert therapeutic effects by modulating the JAK2/STAT1 signaling axis, a key regulator of inflammation and immune dysregulation in sepsis (Yin et al., 2024). This evidence concerns the gene JAK2 and myelofibrosis.